Roxana Mehran and C. Michael Gibson discuss 3-month and 1-month DAPT after everolimus-eluting stents in high-bleeding-risk patients.

Steven Steinhubl and C. Michael Gibson discuss 3-year outcomes in a nationwide, randomized, pragmatic clinical trial of A-fib screening.

Damien Collison and C. Michael Gibson discuss a randomized trial of physiology-guided PCI optimization.

A. Michael Lincoff and C. Michael Gibson discuss CV outcomes with omega-3 carboxylic acids in patients with high vascular risk and atherogenic dyslipidemia.

Dean Kereiakes and C. MIchael Gibson discuss a randomized trial of a novel, ultra-low-profile fixed-wire DES.

Robert Harrington and C. Michael Gibson discuss the registry's design, implementation, and initial results.

Ehrin Armstrong and C. Michael Gibson discuss a randomized, dose-escalation trial of temsirolimus adventitial delivery below the knee.

John Teerlink and C. Michael Gibson discuss omecamtiv mecarbil in chronic HFrEF.

Timothy Henry and C. Michael Gibson discuss outcomes from the North American registry.

Iacopo Olivotto and C. Michael Gibson discuss mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy.